Prostate-specific antigen screening among transgender women in clinical care: A retrospective chart review study
Findings suggest that most trans women/transfeminine persons aged 50+ in our sample had never received PSA screening. Future studies could explore trans women/transfeminine person patient-provider decision-making with respect to PSA screening. Findings reinforce the need for continued discussion of trans women/transfeminine persons' risk of prostate cancer, particularly given inconclusive research evidence to suggest otherwise for those not taking GAHT and call for clarity in PSA screening guidelines for this population to promote health equity.
Authors
- Monica Brundage
- Quang Nguyen (ORCID: https://orcid.org/0009-0000-6309-855X)
- Mona Loutfy (ORCID: https://orcid.org/0000-0001-7887-8997)
- John E Goodhew
- Ashley Lacombe‐Duncan (ORCID: https://orcid.org/0000-0002-9023-8877)
- Angela Underhill (ORCID: https://orcid.org/0000-0002-5427-4862)
- Adrien Saucier
- Gabi Celia Ortiz
Institutions
- Boston College (US)
- Wellesley Institute (CA)
- Women's College Hospital (CA)
- Montreal Police Service (CA)
- Public Health Ontario (CA)
- Maple Leaf Medical Clinic (CA)
Publication Details
- Journal
- Urologic Oncology Seminars and Original Investigations
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1016/j.urolonc.2025.07.017
- Citations
- 1
- Primary Topic
- LGBTQ Health, Identity, and Policy
- Type
- article
- Field-Weighted Citation Impact
- 2.44